Arvinas to Participate in Upcoming Investor Conferences
02 Noviembre 2023 - 5:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
five upcoming investor conferences:
- Truist Securities BioPharma Symposium on
Wednesday, November 8.
- Sean Cassidy, chief financial officer, and Ron Peck, M.D.,
chief medical officer will be available to participate in
one-on-one meetings.
- Stifel Healthcare Conference on Tuesday,
November 14.
- John Houston, Ph.D., chairperson, chief executive officer, and
president, and Ron Peck, M.D., chief medical officer, will be
available to participate in one-on-one meetings and will
participate in a fireside chat. A live audio webcast of the
presentation will be on the Events + Presentations section of the
Company’s website.
- Jefferies London Healthcare Conference on
Thursday, November 16.
- John Houston, Ph.D., chairperson, chief executive officer, and
president, and Sean Cassidy, chief financial officer will be
available to participate in one-on-one meetings.
- Piper Sandler 35th Annual Healthcare
Conference on Tuesday, November 28.
- Ian Taylor, Ph.D., chief scientific officer, and Randy Teel,
Ph.D., senior vice president, corporate and business development,
will be available to participate in one-on-one meetings and will
participate in a fireside chat. A live audio webcast of the
presentation will be on the Events + Presentations section of the
Company’s website.
- 6th Annual Evercore ISI HealthCONx
Conference on Thursday, November 30.
- Ron Peck, M.D., chief medical officer and Jeff Boyle, vice
president, investor relations, will be available to participate in
one-on-one meetings and will participate in a fireside chat. A live
audio webcast of the presentation will be on the Events +
Presentations section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs: ARV-766
and bavdegalutamide for the treatment of men with metastatic
castration-resistant prostate cancer; and vepdegestrant (ARV-471)
for the treatment of patients with locally advanced or metastatic
ER+/HER2- breast cancer. For more information, visit
www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203)
584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Arvinas (NASDAQ:ARVN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024